AstraZeneca Signs US$6 B ADC Collaboration with Daiichi Sankyo for DS-1062

By Michelle Liu

Pharma Deals Review: Vol 2020 Issue 7 (Table of Contents)

Published: 31 Jul-2020

DOI: 10.3833/pdr.v2020.i7.2552     ISSN: 1756-7874

Section: Licensing



In their second antibody drug conjugate (ADC) partnership together, AstraZeneca has agreed to collaborate with Daiichi Sankyo to develop and commercialise its Phase I candidate DS-1062 for the treatment of solid tumours connected to the TROP2 gene, such as non-small cell lung cancer...

This page is available to subscribers only.

Not a subscriber? Join here

Why should I subscribe?

Already Registered? Please login using the top left purple box.

Copyright: © IQVIA 2018

IQVIA™ Pharma Deals: PharmaDeals Review: Article Details